Enliven Therapeutics, Inc.
ELVN · XNASCIK 1672619fmd_0DVT71DQ3FGGS7A65WVX3K2746Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Realized investment gains (losses) | – | – | – | 0 | – | – | – |
| Research and development | 19 | 32 | 20 | 31 | 65 | 81 | 86 |
| Total operating expenses | 24 | 42 | 25 | 39 | 84 | 105 | 120 |
| Operating income | (24) | (42) | (25) | (39) | (84) | (105) | (120) |
| Other non-operating income (expense) | 1 | 0 | 0 | 1 | 12 | 16 | 16 |
| Income before taxes | – | – | (51) | 2 | – | – | – |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | 2 | – | – | – |
| Net income | (23) | (41) | (25) | (38) | (72) | (89) | (104) |